EUVIMEDEUVIMED entdecken
Crossref

Ano1 Antisense Therapy Improves Enamel Properties in Molars but not Amelogenesis in a Murine Model of Cystic Fibrosis

Dinne Nedjar, Arnaud Vanden Bossche, Christie Mitri, The Nghia Nguyen, Florian Hermans, Coralie Torrens, Nicolas Roubier, Elsa Vennat, David Montero, Lotfi Slimani, Hubert Marotte, Catherine Chaussain und 2 weitere

Calcified Tissue International · 27.04.2026 · 117 (1)

DOI: 10.1007/s00223-026-01500-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Calcified Tissue International, online erschienen am 27.04.2026. Verfasst von Dinne Nedjar und 13 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, Inserm UMR_S 1333 Oral Health, 1 Rue Maurice Arnoux, 92120, Montrouge, France. Hauptthemen laut MEDLINE: Cystic Fibrosis, Anoctamin-1, Oligonucleotides, Antisense, Dental Enamel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: France Life Imaging, Fondation de la Recherche Médicale, Fund for Scientific Research (FWO).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis (CF) is a life-shortening inherited disorder caused by mutations in the gene encoding the Cystic Fibrosis Transmembrane conductance Regulator (CFTR), a protein that controls the transport of chloride ions across cell membranes. Defects in CFTR cause thick mucus, leading to chronic infections and inflammation in multiple organs. Severe mutations, such as G542X, that completely abolish the function of CFTR present major therapeutic challenges. One potential approach is to stimulate an alternative chloride channel, ANO1, which is repressed in patients by the small regulatory molecule microRNA-9. We recently showed that an antisense oligonucleotide (ASO) designed to restore ANO1 activity (Ano1 ASO) improved respiratory and digestive functions in a CF mouse model carrying the pathogenic G542X variant. As patients with severe forms of CF often display enamel defects, we aimed to investigate the impact of Ano1 ASO on enamel of G542X CF mice. Combining multiproxy imaging approaches, our data showed that Ano1 ASO initiated at postnatal day 8 partially rescued the enamel properties in molars, which have mainly formed before the onset of treatment. However, it did not correct enamel maturation in the continuously growing incisor. In contrast to CFTR, there was no significant increase in ANO1 expression in maturation-stage ameloblasts compared to secretion ameloblasts. These findings suggest that while stimulating ANO1 cannot compensate for the absence of CFTR during enamel maturation, it enhances the mechanical properties of the erupted teeth, likely by improving salivary properties. This work identifies a potential avenue for mitigating dental complications in patients with severe CF mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAnoctamin-1Oligonucleotides, AntisenseDental EnamelMolarAnimalsMiceDisease Models, AnimalCystic Fibrosis Transmembrane Conductance RegulatorChloride ChannelsHumans

Stichwörter der Autor:innen

G542X mutationANO1Ameloblast functionAntisense oligonucleotide therapyCystic fibrosisEnamel mineralization

Substanzen

Anoctamin-1ANO1 protein, mouseOligonucleotides, AntisenseCystic Fibrosis Transmembrane Conductance RegulatorChloride Channels

Autor:innen und Institutionen

  • Université Paris Cité, Inserm UMR_S 1333 Oral Health, 1 Rue Maurice Arnoux, 92120, Montrouge, France.
  • Université Jean Monnet, SAINBIOSE 1059, Inserm, Mines Saint-Etienne, 42000, Saint-Etienne, France.
  • Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, 75012, Paris, France.
  • Cardiology and Organ Systems (COS), Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Hasselt University, 3590, Diepenbeek, Belgium.
  • Université Paris Saclay, Centrale-Supélec, ENS Paris-Saclay, CNRS, LMPS, 91190, Gif Sur Yvette Cedex, France.
  • Sorbonne Université, FCMat UAR2482, 75005, Paris, France.

Förderung

  • France Life Imaging
  • Fondation de la Recherche Médicale
  • Fund for Scientific Research (FWO)

Zitieren

APA

Nedjar, D., Bossche, A. V., Mitri, C., Nguyen, T. N., Hermans, F., Torrens, C., Roubier, N., Vennat, E., Montero, D., Slimani, L., Marotte, H., Chaussain, C., Tabary, O., & Tilotta, F. (2026). Ano1 Antisense Therapy Improves Enamel Properties in Molars but not Amelogenesis in a Murine Model of Cystic Fibrosis. Calcified Tissue International, 117(1). https://doi.org/10.1007/s00223-026-01500-2

Vancouver

Nedjar D, Bossche AV, Mitri C, Nguyen TN, Hermans F, Torrens C, et al. Ano1 Antisense Therapy Improves Enamel Properties in Molars but not Amelogenesis in a Murine Model of Cystic Fibrosis. Calcified Tissue International. 2026;117(1). doi:10.1007/s00223-026-01500-2

BibTeX
@article{Nedjar2026,
  author = {Nedjar, Dinne and Bossche, Arnaud Vanden and Mitri, Christie and Nguyen, The Nghia and Hermans, Florian and Torrens, Coralie and Roubier, Nicolas and Vennat, Elsa and Montero, David and Slimani, Lotfi and Marotte, Hubert and Chaussain, Catherine and Tabary, Olivier and Tilotta, Françoise},
  title = {Ano1 Antisense Therapy Improves Enamel Properties in Molars but not Amelogenesis in a Murine Model of Cystic Fibrosis},
  journal = {Calcified Tissue International},
  year = {2026},
  volume = {117},
  number = {1},
  doi = {10.1007/s00223-026-01500-2}
}
Kostenlos starten →